Dina Sigano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1192156/publications.pdf

Version: 2024-02-01

232 papers 11,357 citations

26610 56 h-index 97 g-index

262 all docs $\begin{array}{c} 262 \\ \text{docs citations} \end{array}$

times ranked

262

8511 citing authors

#	Article	IF	CITATIONS
1	Complexes of .NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. Journal of Medicinal Chemistry, 1991, 34, 3242-3247.	2.9	730
2	New nitric oxide-releasing zwitterions derived from polyamines. Journal of Organic Chemistry, 1993, 58, 1472-1476.	1.7	594
3	Chemistry of the Nitric Oxide-Releasing Diazeniumdiolate ("Nitrosohydroxylamineâ€) Functional Group and Its Oxygen-Substituted Derivatives. Chemical Reviews, 2002, 102, 1135-1154.	23.0	428
4	Targeting Nitric Oxide (NO) Deliveryin Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor-α-Induced Apoptosis and Toxicity in the Liver. Journal of Medicinal Chemistry, 1997, 40, 1947-1954.	2.9	268
5	Carbeneâ^'Alkyneâ^'Alkene Cyclization Reactions. Chemical Reviews, 1996, 96, 271-288.	23.0	254
6	Quantitative Measurement of Endogenous Estrogens and Estrogen Metabolites in Human Serum by Liquid Chromatographyâ^Tandem Mass Spectrometry. Analytical Chemistry, 2007, 79, 7813-7821.	3.2	233
7	Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic. Molecular Pharmacology, 2001, 60, 302-309.	1.0	219
8	Nitric Oxide (NO) Donor Molecules. Journal of Cardiovascular Pharmacology, 1995, 25, 674-678.	0.8	213
9	Measuring Fifteen Endogenous Estrogens Simultaneously in Human Urine by High-Performance Liquid Chromatography-Mass Spectrometry. Analytical Chemistry, 2005, 77, 6646-6654.	3.2	206
10	Nitric Oxide-Releasing Polymers Containing the [N(O)NO]-Group. Journal of Medicinal Chemistry, 1996, 39, 1148-1156.	2.9	205
11	Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials, 2000, 21, 9-21.	5.7	205
12	Chemistry of the Diazeniumdiolates. 2. Kinetics and Mechanism of Dissociation to Nitric Oxide in Aqueous Solution. Journal of the American Chemical Society, 2001, 123, 5473-5481.	6.6	199
13	PROGRESSTOWARDCLINICALAPPLICATION OF THENITRICOXIDE–RELEASINGDIAZENIUMDIOLATES. Annual Review of Pharmacology and Toxicology, 2003, 43, 585-607.	4.2	187
14	Estrogen Metabolism and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2012, 104, 326-339.	3.0	174
15	Fifty Years of Diazeniumdiolate Research. From Laboratory Curiosity to Broad-Spectrum Biomedical Advances. ACS Chemical Biology, 2011, 6, 1147-1155.	1.6	161
16	Localizing Antithrombotic and Vasodilatory Activity with a Novel, Ultrafast Nitric Oxide Donor. Journal of Medicinal Chemistry, 1996, 39, 4361-4365.	2.9	144
17	Diazeniumdiolates:. Free Radical Biology and Medicine, 2000, 28, 1463-1469.	1.3	124
18	Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia. Journal of Vascular Surgery, 2008, 47, 173-182.	0.6	122

#	Article	lF	Citations
19	Esterase-Sensitive Nitric Oxide Donors of the Diazeniumdiolate Family:Â In Vitro Antileukemic Activity. Journal of Medicinal Chemistry, 2000, 43, 261-269.	2.9	121
20	Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities. Current Topics in Medicinal Chemistry, 2005, 5, 625-636.	1.0	121
21	Comparison of the NO and HNO Donating Properties of Diazeniumdiolates:  Primary Amine Adducts Release HNO in Vivo. Journal of Medicinal Chemistry, 2005, 48, 8220-8228.	2.9	118
22	Differential Effects of Nonselective Nitric Oxide Synthase (NOS) and Selective Inducible NOS Inhibition on Hepatic Necrosis, Apoptosis, ICAM-1 Expression, and Neutrophil Accumulation during Endotoxemia. Nitric Oxide - Biology and Chemistry, 1997, 1, 404-416.	1.2	117
23	Tumor Cell Responses to a Novel Glutathione S-Transferase–Activated Nitric Oxide-Releasing Prodrug. Molecular Pharmacology, 2004, 65, 1070-1079.	1.0	115
24	Mutations induced by saturated aqueous nitric oxide in the pSP189 supF gene in human Ad293 and E. coli MBM7070 cells. Carcinogenesis, 1993, 14, 1251-1254.	1.3	107
25	Induction of Proliferative Lesions of the Uterus, Testes, and Liver in Swiss Mice Given Repeated Injections of Sodium Arsenate: Possible Estrogenic Mode of Action. Toxicology and Applied Pharmacology, 2000, 166, 24-35.	1.3	105
26	A Glutathione S-Transferase ¨He-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins. Molecular Pharmacology, 2006, 69, 501-508.	1.0	104
27	Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and RelatedO2-Aryl Diazeniumdiolates in Vitro and in Vivo. Journal of Medicinal Chemistry, 2006, 49, 4356-4366.	2.9	102
28	The Secondary Amine/Nitric Oxide Complex Ion R2N[N(O)NO]-as Nucleophile and Leaving Group in SNAr Reactions. Journal of Organic Chemistry, 2001, 66, 3090-3098.	1.7	96
29	DNA Sequence Changes Induced by Two Nitric Oxide Donor Drugs in the supF Assay. Chemical Research in Toxicology, 1994, 7, 628-632.	1.7	90
30	Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. Journal of Experimental Medicine, 2010, 207, 2455-2467.	4.2	86
31	Secondary amine/nitric oxide complex ions, R2N[N(O)NO] O-Functionalization chemistry. Journal of Organic Chemistry, 1992, 57, 6134-6138.	1.7	85
32	Synthesis of Cyclopropylpyrrolidines via Reaction of N-Allyl-N-propargylamides with a Molybdenum Carbene Complex. Effect of Substituents and Reaction Conditions. Journal of Organic Chemistry, 1996, 61, 2268-2272.	1.7	85
33	PABA/NO as an Anticancer Lead:Â Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and in Vitro Activity. Journal of Medicinal Chemistry, 2006, 49, 1157-1164.	2.9	85
34	Comparison of Liquid Chromatography-Tandem Mass Spectrometry, RIA, and ELISA Methods for Measurement of Urinary Estrogens. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 292-300.	1.1	84
35	Stabilization of the Nitric Oxide (NO) Prodrugs and Anticancer Leads, PABA/NO and Double JS-K, through Incorporation into PEG-Protected Nanoparticles. Molecular Pharmaceutics, 2010, 7, 291-298.	2.3	84
36	Nitric Oxide Releasing Polyurethanes with Covalently Linked Diazeniumdiolated Secondary Amines. Biomacromolecules, 2006, 7, 987-994.	2.6	83

#	Article	IF	Citations
37	Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer among Premenopausal Women. Cancer Research, 2012, 72, 696-706.	0.4	83
38	Chemistry of the Diazeniumdiolates I. Structural and Spectral Characteristics of the [N(O)NO]â´´ Functional Group. Nitric Oxide - Biology and Chemistry, 2001, 5, 377-394.	1.2	82
39	Deuterium Isotope Effect on the Carcinogenicity of Dimethylnitrosamine in Rat Liver 2. Journal of the National Cancer Institute, 1973, 51, 299-302.	3.0	80
40	The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology, 2003, 37, 324-333.	3.6	78
41	Complexes of Nitric Oxide with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide. Journal of Cardiovascular Pharmacology, 1993, 22, 287-292.	0.8	77
42	Materials from peptide assembly: towards the treatment of cancer and transmittable disease. Current Opinion in Chemical Biology, 2011, 15, 427-434.	2.8	75
43	Mechanism of Vascular Relaxation Induced by the Nitric Oxide (NO)/Nucleophile Complexes, a New Class of NO-Based Vasodilators. Journal of Cardiovascular Pharmacology, 1993, 21, 670-676.	0.8	72
44	A liquid chromatography–mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nature Protocols, 2007, 2, 1350-1355.	5.5	72
45	Thwarting thrombus. Nature Materials, 2003, 2, 357-358.	13.3	70
46	O2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO–NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies. Bioorganic and Medicinal Chemistry, 2007, 15, 4767-4774.	1.4	70
47	Nickel-aluminum alloy as a reducing agent. Chemical Reviews, 1989, 89, 459-502.	23.0	68
48	Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radical Biology and Medicine, 2008, 44, 73-81.	1.3	67
49	HNO and NO Release from a Primary Amine-Based Diazeniumdiolate As a Function of pH. Inorganic Chemistry, 2011, 50, 3262-3270.	1.9	67
50	Nitric Oxide Inhibits Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia by Increasing the Ubiquitination and Degradation of UbcH10. Cell Biochemistry and Biophysics, 2011, 60, 89-97.	0.9	67
51	The Nitric Oxide Prodrug JS-K Is Effective against Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 313-320.	1.3	64
52	Augmentation of Intrapericardial Nitric Oxide Level by a Prolonged-Release Nitric Oxide Donor Reduces Luminal Narrowing After Porcine Coronary Angioplasty. Circulation, 2002, 105, 2779-2784.	1.6	63
53	Chemistry of the Diazeniumdiolates. 3. Photoreactivity. Journal of the American Chemical Society, 2001, 123, 5465-5472.	6.6	62
54	Second-Generation Aspirin and Indomethacin Prodrugs Possessing an $<$ i> $>$ O $<$ i $><$ sup $>$ 2 $<$ sup $>$ -(Acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate Nitric Oxide Donor Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies. Journal of Medicinal Chemistry, 2008, 51, 1954-1961.	2.9	61

#	Article	IF	Citations
55	Inhibition of Oxidized Low-density Lipoprotein-induced Apoptosis in Endothelial Cells by Nitric Oxide. Journal of Biological Chemistry, 2001, 276, 17316-17323.	1.6	59
56	Piperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into Other Biomedically Relevant Functional Molecules. Journal of Organic Chemistry, 1999, 64, 5124-5131.	1.7	57
57	Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses. Cell Reports, 2017, 21, 1169-1179.	2.9	57
58	Reduction of Rat Liver Carcinogenicity of \hat{l}_{\pm} -Nitrosomorpholine by a-Deuterium Substitution 2. Journal of the National Cancer Institute, 1976, 57, 1311-1313.	3.0	54
59	A kinetic investigation of intermediates formed during the Fenton reagent mediated degradation of N-nitrosodimethylamine: evidence for an oxidative pathway not involving hydroxyl radical. Chemical Research in Toxicology, 1991, 4, 510-512.	1.7	54
60	TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Research, 2008, 10, R44.	2.2	54
61	Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. Journal of Vascular Surgery, 2010, 51, 1248-1259.	0.6	52
62	Dual Mechanisms of HNO Generation by a Nitroxyl Prodrug of the Diazeniumdiolate (NONOate) Class. Journal of the American Chemical Society, 2010, 132, 16526-16532.	6.6	52
63	O2-Vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate Protection Againstd-Galactosamine/Endotoxin-Induced Hepatotoxicity in Mice: Genomic Analysis Using Microarrays. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 18-25.	1.3	51
64	Facile hydrogen isotope exchange as evidence for an .alphanitrosamino carbanion. Journal of the American Chemical Society, 1970, 92, 5747-5748.	6.6	50
65	Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT. Toxicology Letters, 2001, 119, 103-108.	0.4	49
66	The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced nephrotoxicity in mice. Toxicology, 2003, 189, 173-180.	2.0	48
67	Nitric Oxide-Releasing Fabrics and Other Acrylonitrile-Based Diazeniumdiolates. Journal of the American Chemical Society, 2007, 129, 3786-3787.	6.6	46
68	Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorganic and Medicinal Chemistry, 2008, 16, 9764-9771.	1.4	46
69	Selective opening of the blood—brain barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. Journal of Neurosurgery, 2003, 99, 728-737.	0.9	45
70	Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. Journal of Virology, 2003, 77, 10227-10236.	1.5	44
71	Growthâ€inhibitory and chemosensitizing effects of the glutathioneâ€ <i>S</i> â€transferaseâ€ï€â€activated nitric oxide donor PABA/NO in malignant gliomas. International Journal of Cancer, 2012, 130, 1184-1194.	2.3	44
72	Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors. Antimicrobial Agents and Chemotherapy, 2016, 60, 190-197.	1.4	44

#	Article	IF	Citations
73	Reduction of nitrosamines with aqueous titanium trichloride: convenient preparation of aliphatic hydrazines. Journal of Organic Chemistry, 1984, 49, 3470-3473.	1.7	43
74	V-PYRRO/NO: AN HEPATO-SELECTIVE NITRIC OXIDE DONOR IMPROVES PORCINE LIVER HEMODYNAMICS AND FUNCTION AFTER ISCHEMIA REPERFUSION1. Transplantation, 2001, 71, 193-198.	0.5	42
75	JS-K, a Glutathione S-Transferase–Activated Nitric Oxide Donor With Antineoplastic Activity in Malignant Gliomas. Neurosurgery, 2012, 70, 497-510.	0.6	42
76	Nitric oxide and ethylnitrosourea: relative mutagenicity in the p53 tumor suppressor and hypoxanthine-phosphoribosyltransferase genes. Carcinogenesis, 1995, 16, 2069-2074.	1.3	41
77	Hydrolytic Reactivity Trends among Potential Prodrugs of the O ² -Glycosylated Diazeniumdiolate Family. Targeting Nitric Oxide to Macrophages for Antileishmanial Activity. Journal of Medicinal Chemistry, 2008, 51, 3961-3970.	2.9	40
78	Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 5198-5220.	2.9	40
79	Nuclear Magnetic Resonance Study of Oxiranes from Ephedrine Salts1a. Journal of Organic Chemistry, 1966, 31, 3921-3924.	1.7	38
80	Nitric Oxide (NO) Releasing Poly ADP-ribose Polymerase 1 (PARP-1) Inhibitors Targeted to Glutathione S-Transferase P1-Overexpressing Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 2292-2302.	2.9	36
81	JS-K; a nitric oxide-releasing prodrug, modulates \hat{l}^2 -catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism. Biochemical Pharmacology, 2010, 80, 1641-1649.	2.0	35
82	Safe disposal of carcinogenic nitrosamines. Carcinogenesis, 1983, 4, 315-319.	1.3	34
83	Diethylamine/Nitric Oxide (NO) Adduct, an NO Donor, Produces Potent Pulmonary and Systemic Vasodilation in Intact Newborn Lambs. Journal of Cardiovascular Pharmacology, 1994, 23, 113-119.	0.8	34
84	Pharmacokinetics and consistency of pericardial delivery directed to coronary arteries: Direct comparison with endoluminal delivery. Clinical Cardiology, 1999, 22, 10-16.	0.7	34
85	The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochemical Pharmacology, 2015, 93, 389-400.	2.0	34
86	Deuterium isotope effect on metabolism of N-nitrosodimethylamine in vivo in rat. Carcinogenesis, 1983, 4, 821-825.	1.3	33
87	Mutagenicity of glyceryl trinitrate (nitroglycerin) in Salmonella typhimurium. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1993, 298, 187-195.	1.2	33
88	Boundary Layer Infusion of Nitric Oxide Reduces Early Smooth Muscle Cell Proliferation in the Endarterectomized Canine Artery. Journal of Surgical Research, 1997, 67, 26-32.	0.8	33
89	Chemistry of the Diazeniumdiolates. O- versus N-Alkylation of the RNH[N(O)NO]-lon. Journal of the American Chemical Society, 2004, 126, 12880-12887.	6.6	33
90	Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas. Neuro-Oncology, 2011, 13, 203-211.	0.6	33

#	Article	lF	CITATIONS
91	The Fenton degradation as a nonenzymic model for microsomal denitrosation of N-nitrosodimethylamine. Chemical Research in Toxicology, 1989, 2, 247-253.	1.7	32
92	Differential Binding Modes of Diacylglycerol (DAG) and DAG Lactones to Protein Kinase C (PK-C). Journal of Medicinal Chemistry, 2003, 46, 1571-1579.	2.9	32
93	V-PROLI/NO, a Prodrug of the Nitric Oxide Donor, PROLI/NO. Organic Letters, 2007, 9, 3409-3412.	2.4	32
94	Preparation of Osmium Hydrazido Complexes by Interception of an Osmium(IV) Imido Intermediate. Journal of the American Chemical Society, 1994, 116, 3649-3650.	6.6	31
95	Conformationally Constrained Analogues of Diacylglycerol. 24. Asymmetric Synthesis of a Chiral (R)-DAG-Lactone Template as a Versatile Precursor for Highly Functionalized DAG-Lactones. Organic Letters, 2004, 6, 2413-2416.	2.4	31
96	Measuring Seven Endogenous Ketolic Estrogens Simultaneously in Human Urine by High-Performance Liquid Chromatographyâ ² Mass Spectrometry. Analytical Chemistry, 2004, 76, 5829-5836.	3.2	31
97	Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H2388-H2398.	1.5	31
98	JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. Journal of Pharmacy and Pharmacology, 2010, 62, 145-151.	1.2	31
99	Diazeniumdiolated carbamates: A novel class of nitric oxide donors. Bioorganic and Medicinal Chemistry, 2012, 20, 2025-2029.	1.4	31
100	An Evaluation of the Roles of Metabolic Denitrosation and \hat{l}_{\pm} -Hydroxylation in the Hepatotoxicity of N-Nitrosodimethylamine. Chemical Research in Toxicology, 1996, 9, 1319-1324.	1.7	30
101	Deamination of Single-Stranded DNA Cytosine Residues in Aerobic Nitric Oxide Solution at Micromolar Total NO Exposures. Chemical Research in Toxicology, 1996, 9, 891-896.	1.7	30
102	Reaction of Nitric Oxide at the \hat{I}^2 -Carbon of Enamines. A New Method of Preparing Compounds Containing the Diazenium diolate Functional Group. Journal of Organic Chemistry, 2000, 65, 5745-5751.	1.7	30
103	JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leukemia Research, 2009, 33, 1525-1529.	0.4	30
104	Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) andO2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as Safe Anti-Inflammatory, Analgesic, Antipyretic, Antioxidant Prodrugs. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 443-450.	1.3	30
105	Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. European Journal of Pharmacology, 2001, 430, 311-315.	1.7	29
106	Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound. Bioorganic and Medicinal Chemistry, 2008, 16, 2657-2664.	1.4	29
107	Poly(diol <i>àê€oâ€</i> citrate)s as Novel Elastomeric Perivascular Wraps for the Reduction of Neointimal Hyperplasia. Macromolecular Bioscience, 2011, 11, 700-709.	2.1	29
108	Nitric Oxide/Nucleophile Complexes. Journal of Cardiovascular Pharmacology, 1993, 22, S3-9.	0.8	28

#	Article	IF	CITATIONS
109	Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. Carcinogenesis, 1996, 17, 2477-2486.	1.3	28
110	Stable isotope dilution high-performance liquid chromatography–electrospray ionization mass spectrometry method for endogenous 2- and 4-hydroxyestrones in human urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 315-330.	1,2	28
111	Nitrite-induced mutations in a forward mutation assay: Influence of nitrite concentration and pH. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1994, 322, 341-346.	1.2	27
112	Diazeniumdiolate Ions as Leaving Groups in Anomeric Displacement Reactions:Â A Protectionâ´´Deprotection Strategy for Ionic Diazeniumdiolates. Journal of the American Chemical Society, 2005, 127, 14188-14189.	6.6	27
113	Assay Reproducibility and Interindividual Variation for 15 Serum Estrogens and Estrogen Metabolites Measured by Liquid Chromatography–Tandem Mass Spectrometry. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2649-2657.	1.1	27
114	Conversion of Proteins to Diazeniumdiolate-Based Nitric Oxide Donors. Bioconjugate Chemistry, 1999, 10, 838-842.	1.8	26
115	An Optimized Protein Kinase C Activating Diacylglycerol Combining High Binding Affinity (Ki) with Reduced Lipophilicity (log P). Journal of Medicinal Chemistry, 2001, 44, 1892-1904.	2.9	26
116	Tailored synthesis of nitric oxide-releasing polyurethanes using O2-protected diazeniumdiolated chain extenders. Journal of Materials Chemistry, 2010, 20, 3107.	6.7	26
117	JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. International Journal of Oncology, 2011, 38, 963-71.	1.4	26
118	Selective Induction of Intestinal Tumors in Rats by Methyl(acetoxymethyl)nitrosamine, an Ester of the Presumed Reactive Metabolite of Dimethylnitrosamine2. Journal of the National Cancer Institute, 1977, 58, 1531-1535.	3.0	24
119	Notes. Reductive destruction of hydrazines as an approach to hazard control. Environmental Science & E	4.6	24
120	Rapid formation of a potent nitrosating agent by solvolysis of ionic nitrite in dichloromethane. Journal of the Chemical Society Chemical Communications, 1987, , 955.	2.0	24
121	Pathophysiology of a Sickle Cell Trait Mouse Model: Human $\hat{l}\pm\hat{l}^2S$ Transgenes with One Mouse \hat{l}^2 -Globin Allele. Blood Cells, Molecules, and Diseases, 2001, 27, 971-977.	0.6	24
122	Nitric Oxide Prodrugs:  Diazeniumdiolate Anions of Hindered Secondary Amines. Organic Letters, 2007, 9, 4551-4554.	2.4	24
123	Reaction of nitric oxide with the imine double bond of certain Schiff bases. Tetrahedron Letters, 1998, 39, 5933-5936.	0.7	23
124	Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 950-953.	1.0	23
125	Cell-Permeable Esters of Diazeniumdiolate-Based Nitric Oxide Prodrugs. Organic Letters, 2008, 10, 5155-5158.	2.4	23
126	"Click―Reaction in Conjunction with Diazeniumdiolate Chemistry: Developing High-Load Nitric Oxide Donors. Organic Letters, 2010, 12, 4256-4259.	2.4	23

#	Article	IF	CITATIONS
127	Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. Nitric Oxide - Biology and Chemistry, 2011, 25, 22-30.	1.2	23
128	The Role of Estrogen Receptor \hat{l}_{\pm} and \hat{l}^{2} in Regulating Vascular Smooth Muscle Cell Proliferation is Based on Sex. Journal of Surgical Research, 2012, 173, e1-e10.	0.8	23
129	Green tea intake is associated with urinary estrogen profiles in Japanese-American women. Nutrition Journal, 2013, 12, 25.	1.5	23
130	Involvement of K+ATPChannels in Nitric Oxide-Induced Inhibition of Spontaneous Contractile Activity of the Nonpregnant Human Myometrium. Biochemical and Biophysical Research Communications, 1998, 253, 653-657.	1.0	22
131	INDUCTION OF PENILE ERECTION BY INTRACAVERNOSAL AND TRANSURETHRAL ADMINISTRATION OF NOVEL NITRIC OXIDE DONORS IN THE CAT. Journal of Urology, 1999, 161, 2013-2019.	0.2	22
132	The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level. Nitric Oxide - Biology and Chemistry, 2005, 12, 114-120.	1.2	22
133	Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs. Journal of Medicinal Chemistry, 2011, 54, 7751-7758.	2.9	22
134	Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status. Free Radical Biology and Medicine, 2011, 50, 1065-1074.	1.3	22
135	Analysis of the HNO and NO donating properties of alicyclic amine diazeniumdiolates. Nitric Oxide - Biology and Chemistry, 2014, 42, 70-78.	1.2	22
136	Conversion of a polysaccharide to nitric oxide-releasing form. dual-mechanism anticoagulant activity of diazeniumdiolated heparin. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 751-753.	1.0	21
137	Nitrogen protonation of N-nitrosodimethylamine. Journal of the American Chemical Society, 1988, 110, 7459-7462.	6.6	20
138	An unusual Bi–Tri–binuclear sandwich complex formed in the reaction of CuCl2with the Et2N–N2O2–ion. Journal of the Chemical Society Chemical Communications, 1993, , 937-939.	2.0	20
139	Conformationally Constrained Analogues of Diacylglycerol (DAG). 27. Modulation of Membrane Translocation of Protein Kinase C (PKC) Isozymes î± and î´ by Diacylglycerol Lactones (DAG-lactones) Containing Rigid-Rod Acyl Groups. Journal of Medicinal Chemistry, 2007, 50, 962-978.	2.9	20
140	Aryl Bis(diazeniumdiolates): Potent Inducers of $\langle i \rangle S \langle i \rangle$ -Glutathionylation of Cellular Proteins and Their in Vitro Antiproliferative Activities. Journal of Medicinal Chemistry, 2008, 51, 7944-7952.	2.9	20
141	Direct Reaction of Amides with Nitric Oxide To Form Diazeniumdiolates. Journal of Organic Chemistry, 2014, 79, 9389-9393.	1.7	20
142	Reaction of nitric oxide with benzyl cyanide to yield a bis-diazeniumdiolated imidate. Tetrahedron Letters, 2000, 41, 8421-8424.	0.7	19
143	Soy Intake is Associated with Increased 2-Hydroxylation and Decreased 16Â-Hydroxylation of Estrogens in Asian-American Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2751-2760.	1.1	19
144	Carcinogenesis and aging. II. Modifying effect of aging on metabolism of methyl(acetoxymethyl)nitrosamine and its interaction with DNA of various tissues in rats. Carcinogenesis, 1983, 4, 967-973.	1.3	18

#	Article	IF	Citations
145	Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide - Biology and Chemistry, 2013, 30, 17-25.	1.2	18
146	Nitric Oxide Reacts with Methoxide. Journal of Organic Chemistry, 2008, 73, 1139-1142.	1.7	17
147	Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H772-H779.	1.5	17
148	N-nitrosothialdine. Synthesis, X-ray crystallography, and N-N rotational barrier. Tetrahedron, 1981, 37, 4143-4149.	1.0	16
149	Chemistry of the Diazeniumdiolates:ÂZ⇌EIsomerism. Journal of the American Chemical Society, 2005, 127, 5388-5395.	6.6	16
150	Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2760-2762.	1.0	16
151	Stability of 15 Estrogens and Estrogen Metabolites in Urine Samples under Processing and Storage Conditions Typically Used in Epidemiologic Studies. International Journal of Biological Markers, 2010, 25, 185-194.	0.7	16
152	Novel protection–deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO. Chemical Communications, 2011, 47, 6710.	2,2	16
153	Preparation of 2′-deoxyxanthosine by nitrosative deamination of 2′-deoxyguanosine under alkaline aqueous conditions. Tetrahedron Letters, 1989, 30, 1467-1468.	0.7	15
154	A Nitric Oxide-Releasing Polydiazeniumdiolate Derived from Acetonitrile. Organic Letters, 2002, 4, 1323-1325.	2.4	15
155	Conformationally Constrained Analogues of Diacylglycerol. 20. The Search for an Elusive Binding Site on Protein Kinase C through Relocation of the Carbonyl Pharmacophore Along thesn-1 Side Chain of 1,2-Diacylglycerol Lactones. Journal of Medicinal Chemistry, 2004, 47, 644-655.	2.9	15
156	Conformationally Constrained Analogues of Diacylglycerol. 21. A Solid-Phase Method of Synthesis of Diacylglycerol Lactones as a Prelude to a Combinatorial Approach for the Synthesis of Protein Kinase C Isozyme-Specific Ligands. Journal of Medicinal Chemistry, 2004, 47, 3248-3254.	2.9	15
157	Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450. Nitric Oxide - Biology and Chemistry, 2006, 14, 309-315.	1.2	15
158	Molecular Basis for Failure of "Atypical―C1 Domain of Vav1 to Bind Diacylglycerol/Phorbol Ester. Journal of Biological Chemistry, 2012, 287, 13137-13158.	1.6	15
159	Extent of DNA 2-hydroxyethylation by N-nitrosomethylethylamine and N-nitrosodiethylamine in vivo. Carcinogenesis, 1986, 7, 1335-1337.	1.3	14
160	Preparation of a thallium(I) diazotate. Structure, physicochemical characterization, and conversion to novel N-nitroso compounds. Journal of the American Chemical Society, 1988, 110, 2800-2806.	6.6	14
161	Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug. Journal of Pharmaceutical Sciences, 2006, 95, 108-115.	1.6	14
162	Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. Bioorganic and Medicinal Chemistry, 2012, 20, 3094-3099.	1.4	14

#	Article	IF	Citations
163	Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using \hat{l}^2 -galactosidase. Nitric Oxide - Biology and Chemistry, 2013, 35, 131-136.	1.2	14
164	Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells. Leukemia Research, 2014, 38, 377-382.	0.4	14
165	Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics, 2009, 94, 32-38.	1.3	13
166	Displacement of O- N-substituents from nitrosamine-derived diazenium ions by three divergent mechanisms. Tetrahedron Letters, 1988, 29, 2903-2906.	0.7	12
167	Hepatic cytochrome P450 2B-type induction by ethyl/phenyl-substituted congeners of phenobarbital in the rat. Chemical Research in Toxicology, 1993, 6, 180-187.	1.7	12
168	N-Nitrosated N-hydroxyguanidines are nitric oxide-releasing diazeniumdiolates. Chemical Communications, 1998, , 1191-1192.	2.2	12
169	Analysis of Vasodilator Responses to Novel Nitric Oxide Donors in the Hindquarters Vascular Bed of the Cat. Journal of Cardiovascular Pharmacology, 2001, 38, 120-129.	0.8	12
170	Conformationally Constrained Analogues of Diacylglycerol. 26. Exploring the Chemical Space Surrounding the C1 Domain of Protein Kinase C with DAG-Lactones Containing Aryl Groups at thesn-1 andsn-2 Positions. Journal of Medicinal Chemistry, 2006, 49, 3185-3203.	2.9	12
171	Formation of complexed nitrosamines by oxidation of coordinated ammonia in the presence of secondary amines. Journal of the American Chemical Society, 1988, 110, 6884-6885.	6.6	11
172	Conformationally Constrained Analogues of Diacylglycerol (DAG). 23â€. Hydrophobic Ligandâ^Protein Interactions versus Ligandâ^Lipid Interactions of DAG-Lactones with Protein Kinase C (PK-C). Journal of Medicinal Chemistry, 2004, 47, 4858-4864.	2.9	11
173	Carbon-Bound Diazeniumdiolates from the Reaction of Nitric Oxide with Amidines. Journal of Organic Chemistry, 2005, 70, 7647-7653.	1.7	11
174	Conformationally Constrained Analogues of Diacylglycerol (DAG). 28. DAG-dioxolanones Reveal a New Additional Interaction Site in the C1b Domain of PKCδ. Journal of Medicinal Chemistry, 2007, 50, 3465-3481.	2.9	11
175	Vâ€PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenicâ€induced toxicity. Cancer Science, 2009, 100, 382-388.	1.7	11
176	A symmetrically hydrogen-bonded binitrosamine cation produced on protonation of N-nitrosopyrrolidine. Journal of the American Chemical Society, 1988, 110, 3701-3702.	6.6	10
177	ADDUCTS OF PIPERAZINE WITH NITRIC OXIDE. Organic Preparations and Procedures International, 1999, 31, 189-192.	0.6	10
178	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biology and Therapy, 2020, 21, 223-230.	1.5	10
179	Spectral and other properties of some oxygenated derivatives of benzo[a]pyrene. Journal of Chemical & Lamp; Engineering Data, 1973, 18, 332-334.	1.0	9
180	The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. Cancer Letters, 2007, 256, 238-245.	3.2	9

#	Article	IF	CITATIONS
181	Glycosylated PROLI/NO Derivatives as Nitric Oxide Prodrugs. Organic Letters, 2010, 12, 56-59.	2.4	9
182	<i>N</i> â€Methylâ€Substituted Fluorescent DAG–Indololactone Isomers Exhibit Dramatic Differences in Membrane Interactions and Biological Activity. ChemBioChem, 2011, 12, 2331-2340.	1.3	9
183	O ² -Functionalized Methylamine Diazeniumdiolates: Evidence for <i>E</i> â‡,, <i>Z</i> Equilibration in an Acyclic System. Journal of Organic Chemistry, 2012, 77, 10804-10810.	1.7	9
184	Magnesium hydroxide as a thin-layer chromatographic adsorbent. Journal of Chromatography A, 1967, 31, 390-395.	1.8	8
185	Analysis of mixtures of isomeric polynuclear hydrocarbons by nuclear magnetic resonance spectrometry. Methylated derivatives of anthracene, benz[.alpha.]anthracene, benzo[c]phenanthrene, and pyrene. Analytical Chemistry, 1971, 43, 1411-1416.	3.2	8
186	Stereochemistry of thialdine. Journal of Heterocyclic Chemistry, 1982, 19, 1301-1304.	1.4	8
187	Improved synthesis of V-PYRRO/NO, a liver-selective nitric oxide prodrug, and analogues. Tetrahedron Letters, 2009, 50, 2069-2071.	0.7	8
188	Ceramides: Branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency. Bioorganic and Medicinal Chemistry, 2009, 17, 1498-1505.	1.4	8
189	Magnesium hydrogen as a thin-layer chromatographic adsorbent II. A unique system for separating polynuclear azaaromatic compounds. Journal of Chromatography A, 1970, 47, 20-26.	1.8	7
190	Magnesium hydroxide as a thin-layer chromatographic adsorbent. Journal of Chromatography A, 1972, 69, 215-218.	1.8	7
191	Isolation of stable 1:1 and 2:1 salts of nitrosamines with protic acids. Journal of Organic Chemistry, 1989, 54, 2432-2436.	1.7	7
192	Mechanistic insight into exclusive nitric oxide recovery from a carbon-bound diazeniumdiolate. Nitric Oxide - Biology and Chemistry, 2002, 7, 103-108.	1.2	7
193	Deamidation of peptides in aerobic nitric oxide solution by a nitrosative pathway. Nitric Oxide - Biology and Chemistry, 2006, 14, 144-151.	1.2	7
194	The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline. ACS Medicinal Chemistry Letters, 2010, 1, 386-389.	1.3	7
195	PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells. Bioorganic and Medicinal Chemistry, 2015, 23, 4980-4988.	1.4	7
196	Decomposition and quality control considerations in biological work with fecapentaene preparations. Chemical Research in Toxicology, 1989, 2, 162-168.	1.7	6
197	Decoding Nitric Oxide Release Rates of Amine-Based Diazeniumdiolates. Journal of Physical Chemistry A, 2013, 117, 6671-6677.	1.1	6
198	Stereoselectivity in the microsomal conversion of N-nitrosodimethylamine to formaldehyde. Chemical Research in Toxicology, 1990, 3, 540-544.	1.7	5

#	Article	IF	Citations
199	North†and Southâ€Bicyclo[3.1.0]Hexene Nucleosides: The Effect of Ring Planarity on Antiâ€HIV Activity. ChemMedChem, 2009, 4, 1354-1363.	1.6	5
200	Nitrogen-bound diazenium diolated amidines. Chemical Communications, 2010, 46, 5799.	2.2	5
201	Cross-Linking Protein Glutathionylation Mediated by O2-Arylated Bis-Diazeniumdiolate "Double JS-K― Chemical Research in Toxicology, 2012, 25, 2670-2677.	1.7	5
202	\hat{l}^2 -Deuteration of N-nitrosoethylmethylamine causes a shift in DNA methylation from rat liver to esophagus. Carcinogenesis, 1991, 12, 545-549.	1.3	4
203	Preparation and Reactivity of O2-Sulfonated Diazenium diolates. Journal of Organic Chemistry, 2003, 68, 656-657.	1.7	4
204	Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. Chemico-Biological Interactions, 2011, 193, 88-96.	1.7	4
205	Diacylglycerol Lactones Targeting the Structural Features That Distinguish the Atypical C1 Domains of Protein Kinase C \hat{l}^q and \hat{l}^1 from Typical C1 Domains. Journal of Medicinal Chemistry, 2014, 57, 3835-3844.	2.9	4
206	Photochemical perturbation of Z⇌E equilibria in nitrosamines. Journal of the Chemical Society Chemical Communications, 1976, , 633-634.	2.0	3
207	SYNTHESIS OF THE SELECTIVE BLADDER CARCINOGEN, N-(<i>>n-(i>-BUTYL)-N-(3-CARBOXYPROPYL)NITROSAMINE (BCPN). Organic Preparations and Procedures International, 1977, 9, 49-52.</i>	0.6	3
208	Single-dose toxicokinetics of N-nitrosomethylethylamine and N-nitrosomethyl (2,2,2-trideuterioethyl)amine in the rat. Archives of Toxicology, 1990, 64, 109-115.	1.9	3
209	Ion-Pairing Systems for Separation of <i>N</i> -Nitrosodimethylamine and its Metabolites in Reversed-Phase High-Performance Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 195-206.	0.9	3
210	Quantification of Diazeniumdiolate Mutagenicity in Four Differentin VitroAssays. Nitric Oxide - Biology and Chemistry, 1997, 1, 158-166.	1.2	3
211	l-Tyrosine and nitric oxide synergize to prevent cytotoxic effects of superoxide. Toxicology, 2001, 165, 163-170.	2.0	3
212	An improved synthesis of V-PROLI/NO, a cytochrome P450-activated nitric oxide prodrug. Tetrahedron Letters, 2009, 50, 4545-4548.	0.7	3
213	Primary amine diazeniumdiolate ions of structure {RNN(O)NOR′}â^' as ambident nucleophiles. Tetrahedron Letters, 2009, 50, 5917-5919.	0.7	3
214	Arylation of Sensitive 1-(Pyrrolidin-1-yl)-diazen-1-ium-diolate in Ionic Liquids. Synthetic Communications, 2010, 40, 1322-1332.	1.1	3
215	Synthesis, analysis, and stability studies of 14C-methyl(acetoxymethyl)nitrosamine. Journal of Labelled Compounds and Radiopharmaceuticals, 1981, 18, 1261-1272.	0.5	2
216	Membraneâ€Surface Anchoring of Charged Diacylglycerolâ€Lactones Correlates with Biological Activities. ChemBioChem, 2010, 11, 2003-2009.	1.3	2

#	Article	IF	CITATIONS
217	Diazeniumdiolates (Formerly NONOates) in Cardiovascular Research and Potential Clinical Applications., 0,, 431-446.		2
218	Tritium gas exposure as an alternative to base-catalyzed exchange for the one-step tritiation of nitrosamines. Journal of Labelled Compounds and Radiopharmaceuticals, 1978, 14, 91-97.	0.5	1
219	Unexpected Incorporation of Bromine at a Non-anomeric Position during the Synthesis of an O2-Glycosylated Diazeniumdiolate. Organic Preparations and Procedures International, 2009, 41, 143-147.	0.6	1
220	Nitrous oxide as a primary product in base-mediated \hat{l}^2 -elimination reactions of diazenium diolated benzylamine derivatives. Chemical Communications, 2012, 48, 5931.	2.2	1
221	JS-K, a Novel Nitric Oxide (NO) Generator, Induces Cytochrome c Release and Caspase Activation in HL-60 Myeloid Leukemia Cells Blood, 2004, 104, 3415-3415.	0.6	1
222	Focal Suppression and Induction of Hyperplasia by the Bladder Carcinogens Butyl(4-hydroxybutyl)nitrosamine and Butyl(3-carboxypropyl)nitrosamine in Organ-Cultured Rat Bladder Epithelium. Journal of the National Cancer Institute, 1978, 60, 219-223.	3.0	0
223	Possible Mechanisms of Nitrosamine Formation in Pesticides. ACS Symposium Series, 1981, , 133-147.	0.5	O
224	Determination of 3-methyl-4,5-dihydro-1,2,3-oxadiazolium ion, a putative nitrosamine metabolite, by ion-pair chromatography with electrochemical detection. Analytica Chimica Acta, 1990, 232, 397-400.	2.6	0
225	Mixed ligand, non-nitrosyl Cu(II) complexes as potential cardiovascular agents via no release Journal of Inorganic Biochemistry, 1992, 47, 47.	1.5	0
226	Qualitative Thin-Layer and High-Performance Liquid Chromatographic Analysis of 1-Substituted Diazen-1-ium-1,2-diolates on Aminopropyl-Bonded Silica Gel. Analytical Biochemistry, 2002, 301, 97-102.	1.1	0
227	Inside Cover: Membrane-Surface Anchoring of Charged Diacylglycerol-Lactones Correlates with Biological Activities (ChemBioChem 14/2010). ChemBioChem, 2010, 11, 1926-1926.	1.3	0
228	Richard Loeppky (1937–2012). Chemical Research in Toxicology, 2012, 25, 1155-1156.	1.7	0
229	Stereochemical Origins of Chromophore Extension in O2-Substituted Diazeniumdiolates, Prodrugs of Nitric Oxide. Journal of Chemical Crystallography, 2013, 43, 123-126.	0.5	0
230	Aminolysis of an N-Diazeniumdiolated Amidine as an Approach to Diazeniumdiolated Ammonia. Journal of Organic Chemistry, 2014, 79, 4512-4516.	1.7	0
231	JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells Blood, 2005, 106, 1593-1593.	0.6	0
232	Abstract 3334: GSTP1-activated nitric oxide-releasing/PARP inhibitor hybrid prodrugs induce cancer cell death through ROS/RNS, DNA damage, ER stress, and apoptosis , 2013, , .		0